Activated PI3K and RTK signaling and response/resistance to HER2 targeted therapy

被引：0
|
作者：
O'Brien, Neil
Browne, Brigid
Chow, Lucy
Ginther, Charles
Bensadigh, Brian
Atefi, Mohammad
Arboleda, Jane
Duffy, Michael
Crown, John
O'Donovan, Norma
Slamon, Dennis
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Natl Inst Cellular Biotechnol, Dublin, Ireland
[3] Conway Inst, UCD Sch Med & Med Sci, Dublin, Ireland
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
765
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.
    She, Q.-B.
    Chandarlapaty, S.
    Ye, Q.
    Lobo, J.
    Haskell, K. M.
    Leander, K. R.
    DeFeo-Jones, D.
    Huber, H. E.
    Rosen, N.
    CANCER RESEARCH, 2009, 69 (02) : 222S - 222S
  • [22] The role of Her2 and other oncogenes of the PI3K/AKT pathway in mitochondria
    Rohlenova, Katerina
    Neuzil, Jiri
    Rohlena, Jakub
    BIOLOGICAL CHEMISTRY, 2016, 397 (07) : 607 - 615
  • [23] PI3K targeted inhibition in NSCLC: An in vitro evaluation and correlation of mutation status to activated PI3K pathway signaling in NSCLC patients
    Heavey, Susan
    Toomey, Sinead
    Carr, Aoife
    Cuffe, Sinead
    Finn, Stephen
    Hennessy, Bryan
    Crown, John
    Barr, Martin
    O'Byrne, Kenneth
    Gately, Kathy
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (07)
  • [24] Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
    Junttila, Teemu T.
    Akita, Robert W.
    Parsons, Kathryn
    Fields, Carter
    Phillips, Gail D. Lewis
    Friedman, Lori S.
    Sampath, Deepak
    Sliwkowski, Mark X.
    CANCER CELL, 2009, 15 (05) : 429 - 440
  • [25] Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer (vol 77, pg 3280, 2017)
    Hanker, Ariella B.
    Estrada, Monica Valeria
    Bianchini, Giampaolo
    Moore, Preston D.
    Zhao, Junfei
    Cheng, Feixiong
    Koch, James P.
    Gianni, Luca
    Tyson, Darren R.
    Sanchez, Violeta
    Rexer, Brent N.
    Sanders, Melinda E.
    Zhao, Zhongming
    Stricker, Thomas P.
    Arteaga, Carlos L.
    CANCER RESEARCH, 2019, 79 (04) : 873 - 873
  • [26] PI3Kβ-A Versatile Transducer for GPCR, RTK, and Small GTPase Signaling
    Bresnick, Anne R.
    Backer, Jonathan M.
    ENDOCRINOLOGY, 2019, 160 (03) : 536 - 555
  • [27] hMENA11a contributes to HER3-mediated resistance to PI3K inhibitors in HER2 overexpressing breast cancer cells
    Trono, Paola
    Di Modugno, Francesca
    Circo, Rita
    Spada, Sheila
    Melchionna, Roberta
    Palermo, Belinda
    Panetta, Mariangela
    Matteoni, Silvia
    Soddu, Silvia
    De Maria, Ruggero
    Nistico, Paola
    CANCER RESEARCH, 2015, 75
  • [28] Response and resistance factor candidates to HER2 targeted therapy in gastric cancer (GC)
    Lordick, F.
    Haffner, I.
    Luber, B.
    Maier, D.
    Kretzschmar, A.
    von Weikersthal, L. Fischer
    Riera-Knorrenschild, J.
    Ahlborn, M.
    Schierle, K.
    Wittekind, C.
    ANNALS OF ONCOLOGY, 2016, 27 : 103 - 103
  • [29] Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway
    Wilks, Sharon T.
    BREAST, 2015, 24 (05): : 548 - 555
  • [30] Acquired resistance to HER2 targeted therapy: A common mechanism
    Christenson, Jessica
    Kane, Susan E.
    CANCER RESEARCH, 2012, 72
12345